G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma
Article 2021 en
Authors
GK
Greg Kelly
FA
Fares Al‐Ejeh
RM
Robert McCuaig
Abstract
1 min read
Checkpoint inhibitor blockade response is limited to a subset of the patient population. These results have implications for the development of LC3B as a predictive biomarker of checkpoint inhibitor blockade to guide patient selection, as well as G9a inhibition as a strategy to extend the proportion of patients responding to immunotherapy.
Greg Kelly, Fares Al‐Ejeh, Robert McCuaig, Francesco Casciello, Nabilah Ahmad Kamal, Blake Ferguson, Antonia L. Pritchard, Sayed Ali, Ines P. Silva, James S. Wilmott, Georgina V. Long, Richard A Scolyer, Sudha Rao, Nicholas K. Hayward, Frank Gannon, Jason S. Lee
Greg Kelly, Fares Al‐Ejeh, Robert McCuaig, Francesco Casciello, Nabilah Ahmad Kamal, Blake Ferguson, Antonia L. Pritchard, Sayed Ali, Ines P. Silva, James S. Wilmott, Georgina V. Long, Richard A Scolyer, Sudha Rao, Nicholas K. Hayward, Frank Gannon, Jason S. Lee
Marcel A. Deken, Jules Gadiot, Ekaterina S. Jordanova, Ruben Lacroix, Melissa van Gool, Paula Kroon, Cristina Pineda, Marnix H. Geukes Foppen, Richard A Scolyer, Ji‐Ying Song, Inge Verbrugge, Christoph Höeller, Reinhard Dummer, John B.A.G. Haanen, Georgina V. Long, Christian U. Blank
Su Yin Lim, Elena Shklovskaya, Jenny Lee, Bernadette Pedersen, Ashleigh Stewart, Zizhen Ming, Mal Irvine, Brindha Shivalingam, Robyn P.M. Saw, Alexander M. Menzies, Matteo S. Carlino, Richard A Scolyer, Georgina V. Long, Helen Rizos
Discussion(0)
No comments yet. Be the first to comment.